C2N Diagnostics Revenue and Competitors

Location

$85M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • C2N Diagnostics's estimated annual revenue is currently $18.1M per year.(i)
  • C2N Diagnostics's estimated revenue per employee is $155,000
  • C2N Diagnostics's total funding is $85M.

Employee Data

  • C2N Diagnostics has 117 Employees.(i)
  • C2N Diagnostics grew their employee count by 27% last year.

C2N Diagnostics's People

NameTitleEmail/Phone
1
Assistant General Counsel and VP Human ResourcesReveal Email/Phone
2
Co-Founder and Senior Advisor for Medical InnovationReveal Email/Phone
3
SVP, R&D and Laboratory OperationsReveal Email/Phone
4
VP, Research and DevelopmentReveal Email/Phone
5
ControllerReveal Email/Phone
6
SVPReveal Email/Phone
7
Director Research and DevelopmentReveal Email/Phone
8
Senior Director, Corporate CommunicationsReveal Email/Phone
9
Senior Director Clinical Chemistry & Commercial AssaysReveal Email/Phone
10
Laboratory and Quality Control ManagerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$79.4M5120%N/AN/A
#2
$1.1M70%N/AN/A
#3
$2.5M1633%N/AN/A
#4
$5M3214%N/AN/A
#5
$1.1M717%N/AN/A
#6
$6M393%N/AN/A
#7
$3.4M22-8%N/AN/A
#8
$0.3M40%N/AN/A
#9
$7.4M4850%N/AN/A
#10
$5.7M370%N/AN/A
Add Company

What Is C2N Diagnostics?

C₂N Diagnostics' vision is to bring Clarity Through Innovation™. It focuses its therapeutic discovery efforts around mechanism-based approaches to prevent or stop the progression of human neurological disorders. Diagnostic efforts revolve around bringing accurate, widely accessible, and cost-effective blood tests to the clinic for the betterment of patient care and brain health monitoring. Its lead commercial product, the PrecivityAD™ blood test, is a mass spectrometry-based test performed in C₂N's CLIA-certified lab that measures in blood multiple analytes including Aβ42, Aβ40, and apolipoprotein E isoforms. While the test by itself cannot diagnose Alzheimer's disease — which is a clinical diagnosis made by a health care provider — the test is an important new tool for physicians to aid in the evaluation process. PrecivityAD™, which can only be ordered through a health care provider, predicts brain amyloid plaques as determined by PET scan results and in 2019 it received a Breakthrough Device Designation from the U.S. Food and Drug Administration. The PrecivityAD™ blood test also has achieved the CE Mark from the European Union. For more information visit www.C2N.com.

keywords:N/A

$85M

Total Funding

117

Number of Employees

$18.1M

Revenue (est)

27%

Employee Growth %

N/A

Valuation

N/A

Accelerator

C2N Diagnostics News

2022-04-17 - JAMA Network Open Publishes Analysis of Results of Two ...

C 2 N Diagnostics, a leader in advanced brain health diagnostics, announced today that the Journal of the ... SOURCE: C2N Diagnostics.

2022-04-17 - Race of people given Alzheimer's blood tests may affect ...

... C2N Diagnostics — was equally effective at detecting early Alzheimer's disease regardless of the race of the person being tested.

2022-04-17 - Does race affect interpretation of Alzheimer's disease tests?

... disease test they developed in previous work (PrecivityAD, C2N Diagnostics) in 76 pairs of Black and non-Hispanic white participants.

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$38.4M11724%N/A
#2
$3.5M11844%N/A
#3
$38.7M1194%N/A
#4
$17.4M12022%N/A
#5
$18.6M120-6%$172M